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Background: Podoconiosis is one of the major causes of lymphoedema in the tropics. Nonetheless, currently
there are no endemicity classiﬁcations or elimination targets to monitor the effects of interventions. This
study aimed at establishing case deﬁnitions and indicators that can be used to assess endemicity, elimination
and clinical outcomes of podoconiosis.
Methods: This paper describes the result of a Delphi technique used among 28 experts. A questionnaire outlining
possible case deﬁnitions, endemicity classiﬁcations, elimination targets and clinical outcomes was developed.
The questionnaire was distributed to experts working on podoconiosis and other neglected tropical diseases in
two rounds. The experts rated the importance of case deﬁnitions, endemic classiﬁcations, elimination targets
and the clinical outcome measures. Median and mode were used to describe the central tendency of expert
responses. The coefﬁcient of variation was used to describe the dispersals of expert responses.
Results: Consensus on deﬁnitions and indicators for assessing endemicity, elimination and clinical outcomes of
podoconiosis directed at policy makers and health workers was achieved following the two rounds of Delphi
approach among the experts.
Conclusions: Based on the two Delphi rounds we discuss potential indicators and endemicity classiﬁcation of this
disabling disease, and the ongoing challenges to its elimination in countries with the highest prevalence.
Consensus will help to increase effectiveness of podoconiosis elimination efforts and ensure comparability of
outcome data.
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Introduction
The possibility of eradicating and eliminating diseases has been
discussed over several decades.1,2 Historically, several diseases
have been targeted for elimination or eradication including
yellow fever, yaws, malaria and leprosy.3 Smallpox has been era-
dicated, while polio and Guinea worm are in the end stages.4 The
London declaration on neglected tropical diseases includes ambi-
tious goals to eradicate Guinea worm disease, and to eliminate
lymphatic ﬁlariasis, leprosy, sleeping sickness (human African
trypanosomiasis) and blinding trachoma by 2020.5
Establishing elimination targets and endemicity classiﬁcations
is vital for creating a standardized monitoring framework, allowing
effective communication and ultimately ascertaining elimination
of disease. Deﬁning these targets and the associatedmetrics is fun-
damental to creating global consensus on disease control across
endemic countries. Podoconiosis is a geochemical, non-ﬁlarial ele-
phantiasis often occurring in barefoot subsistence farmers who are
in long-term contact with irritant red clay soil of volcanic origin.6
Podoconiosis was ﬁrst identiﬁed in 1980 as an important cause
of tropical lymphoedema, yet still continues to cause signiﬁcant
morbidity.7,8
Globally, podoconiosis has been reported in 25 countries in
tropical Africa, South East Asia and Latin America, with an esti-
mated 4 million cases.9,10 Recently, three countries (Ethiopia,
Cameroon and Rwanda) have taken the initiative to map the
distribution of podoconiosis. As plans for the mapping of podoco-
niosis continue to progress, it is imperative to have targets for
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elimination and a threshold by which to deﬁne endemicity. An
endemicity threshold will help to identify areas considered en-
demic for podoconiosis and requiring interventions. This informa-
tion will be useful for public health policy and planning.
In 2011 WHO identiﬁed podoconiosis as one of the neglected
tropical diseases (NTDs).11 Although this inclusion was an import-
ant step forward, to date there is no clear global strategy for the
elimination or control of podoconiosis. Communities or countries
require a pre-speciﬁed threshold to achieve the goal of elimination
of podoconiosis as a public health problem. For other NTDs, elim-
ination targets and endemicity classiﬁcations are often based
on prevalence of the infective organism. For lymphatic ﬁlariasis
(LF), the target is the reduction of the microﬁlaraemia rate to
below 1% in previously endemic districts.12,13 This is not possible
with podoconiosis, since the agent ismineral rather than biological,
so targets will rather be based on morbidity (lymphoedema)
prevalence.
As global interest in podoconiosis increases it is important to
have clear goals and indicators to measure progress towards
control and elimination. Here we present the results of a Delphi
assessment by experts working on podoconiosis and other NTDs.
The objectives of this paper are 1) produce case deﬁnitions of
podoconiosis for surveillance; 2) identify appropriate endemicity
classes for podoconiosis (non-endemic, hypo-, meso- and hyper-
endemic); 3) identify targets for elimination of podoconiosis from
a country; 4) deﬁne clinical outcomes to monitor progress.
Materials and methods
Description of Delphi techniques
The Delphi survey technique is an iterative email or web-based
survey to reach a consensus among a group of experts who are
familiar with a subject area.14 The approach uses well-designed
sequential surveys in which each round depends on the response
from the previous round. Each round uses feedback from
the previous rounds from the same group of experts. Once
the experts are selected, they are asked to provide judgement
on the concepts of the subject under consideration using open-
ended questions.15 The next phase asks the same panelists
to rank the items based on a Likert scale, measuring their
importance. Following that, several rounds may be needed until
a consensus on each item has been achieved based on the
results of the quantitative analysis.16
Design and participants
We used a Delphi method to deﬁne case deﬁnition, endemicity
class, elimination targets and clinical outcomes of podoconiosis.
We used a four-round Delphi method. In the ﬁrst two rounds a
small group of experts working on podoconiosis were involved in
developing the tool. In the subsequent two rounds a wider
group of experts working on podoconiosis and other NTDs was
involved. These later rounds were conducted from August to
November 2014 (Figure 1).
The selection of experts for the Delphi process was done using
a purposive sampling technique (expert sampling). For the ﬁrst
two rounds, experts with experience in podoconiosis research
and programs were included. For the subsequent two rounds,
the following eligibility criteria were used to select the experts:
individuals working on NTDs at national or global level; individuals
working on podoconiosis research or program management;
senior podoconiosis professionals with in-depth knowledge and
experience of control; experts involved in developing indicators
and targets for other NTDs.
During recruitment, potential experts were approached (initially
via e-mail or by telephone) and provided with a detailed explan-
ation of the study and its objectives. A total of 28 national and
international experts participated in the Delphi analysis process.
Questionnaire development
We developed the questionnaire after review of the literature
and in consultation with podoconiosis experts. Experiences of
developing elimination targets for other diseases were reviewed,
and podoconiosis prevalence estimates from affected coun-
tries17–21 were used to draft the questionnaire. The questionnaire
included general information about the purpose of the study and
the need for targets for podoconiosis control. A list of possible
case deﬁnitions, endemicity classiﬁcations, elimination targets
and monitoring indicators was provided, and respondents were
asked to indicate their agreement or disagreement with each
item and to provide alternative options for each (Supplementary
information and Figure 1).
Data collection and analysis
The case deﬁnitions, endemicity classiﬁcations, elimination
targets and monitoring indicators were developed between
October 2012 and November 2014 in a series of four reiterative
surveys. Feedback on each item was received and the question-
naire was modiﬁed. In the last two rounds, experts were asked
to score items in terms of importance on a 9-point Likert scale
for each indicator ranging from 1=not important to 9=extremely
important.
For this study and in line with other related studies,22,23 we set
the consensus level as follows: 1) consensus of inclusion: >70% of
participants scored the item ≥7; 2) consensus of exclusion: >70%
of participants scored the item ≤5; 3) no consensus: item failed to
meet either of the above criteria. The responses in the ﬁrst-round
survey were analyzed using descriptive statistics and the results
were sent back to the experts for review and ratiﬁcation. Items
which were recommended for modiﬁcation by the experts were
revised and added to the second round questionnaire; new
items suggested by the experts were also added to the second
round questionnaire. In the second questionnaire, participants
were asked to re-rank the items from the ﬁrst round. Second
round Delphi responses that reached 70% consensus were deter-
mined to be appropriate items for assessing different aspects of
podoconiosis elimination. The ﬁnal results were presented to
experts for discussion and ﬁnal consensus, leading to selection
of the ﬁnal targets and indicators.
Median and mode were used to describe the central tendency
of expert responses.15,24,25 The coefﬁcient of variation (CV) was
used to describe the variability of expert responses.15,23 The CV
is the ratio of the standard deviation of the responses of the
experts on a speciﬁc item to its corresponding mean (average).
Therefore, each survey item in each round yielded one CV value.16
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Results
Characteristics of the experts
During the ﬁrst roundof the Delphi survey, questionnaireswere sent
to 35 experts, 28 of whom responded. These 28 experts were
working at global or national level and were based in six countries.
All of the experts had Masters level education or above. Twenty ﬁve
experts responded to the second round survey. Descriptive infor-
mation on the experts is presented in Table 1.
Results of the ﬁrst round Delphi survey
The results of the ﬁrst roundDelphi survey are shown in Table 2. The
median score of items shown in Table 2 ranged from 6.5 to 9.0.
Most of the items had CV score of less than 0.3 indicating good
central tendencies for expert scores, and thus good consensus.
For casedeﬁnitions, themedianandmode scoreswere at least 7.5
and 8.0 respectively. All of the indicators in this category had CV
scores of 0.3 or less. Apart from the ‘probable case’ deﬁnition, the
rest reﬂected at least 70% agreement (≥7) among the experts. The
experts suggested that the ‘probable case’ deﬁnition should bemodi-
ﬁed. In the endemicity category, all the items had amedian score of
at least 7.5 and amode score of 9.0. In this category at least 70% of
experts were in consensus over all the indicators, and apart from the
‘non-endemic’ category, all had CV scores of 0.3 or less.
In the ‘elimination target’ category, of the ten items, nine had
median score≥7.0 andmode score of 9.0. Apart from three items,
consensus was found among 70% or more of the experts. Two
of the items with less than 70% agreement were related to lym-
phoedema management. The experts commented that the term
‘adequate treatment’ should be clearly deﬁned.
In the ‘monitoring clinical outcome’ category, all ﬁve items had
median score of ≥8.0 and mode score of 9.0. Of the ﬁve items,
three reached consensus among >70% of the experts. The two
items with less than 70% agreement were ‘treatment success’
and ‘measure of proper foot hygiene’. In the former, the experts
Figure 1. Flowchart of the Delphi process for the development of case deﬁnitions, endemicity classiﬁcations and elimination targets.
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recommended that the term ‘incapacitated’ should be deﬁned.
They also indicated that the measurement of foot hygiene is
poorly deﬁned, and essentially a subjective measurement.
None of the items fulﬁlled the criteria of consensus of exclu-
sion, therefore none were deleted from the second round of the
survey. In the ‘case deﬁnition’ category, experts suggested that
3 months duration of the symptoms was too short due to the
chronic nature of podoconiosis lymphoedema, so the case deﬁn-
ition was revised to reﬂect lymphoedema duration of at least
1 year. In addition, the experts recommended that long term visi-
tors should not be included in the case deﬁnition since podoconio-
sis requires an extended period of exposure to red clay soil in order
to occur.9,26 Long term visits (deﬁned as at least 6 months) would
not be sufﬁcient exposure for podoconiosis occurrence. For treat-
ment of lymphoedema, the experts indicated that the 90% target
was low and suggested it should be raised to 95% for round 2.
Results of the second round Delphi survey
All of the case deﬁnitions, endemicity classes, elimination targets
and clinical outcomes reached >70% consensus among experts
(Table 3). The median and mode scores ranged between 8.0
and 9.0, and the CV score was less than 0.3 for all of the indicators
and case deﬁnitions, demonstrating a high degree of consensus
among the experts.
Case deﬁnition of podoconiosis for surveillance
Three levels of case deﬁnition were arrived at: 1) suspected case:
any lymphoedema of the lower limb of any duration; 2) probable
case: any lymphoedema of the lower limb present for more than
1 year in a resident of an endemic area; 3) conﬁrmed case:
lymphoedema of the lower limb present for more than 1 year in
a resident of an endemic area, for which other causes (e.g. oncho-
cerciasis, LF, leprosy Milroy syndrome, heart or liver failure) have
been excluded.
Endemicity classiﬁcations
Percentage prevalences were agreed for four endemicity classi-
ﬁcations; ‘non-endemic’, ‘hypo-endemic’, ‘meso-endemic’ and
‘hyper-endemic’ (Table 3), based on knowledge of sub-district
prevalence.
Elimination targets
Consensus was reached on the following elimination targets:
Podoconiosis is deﬁned as being eliminated from an endemic dis-
trict or implementation unit if the prevalence of untreated podo-
coniosis is less than 1% (among individuals ≥15 years old), and
more than 95% of lymphoedema cases are treated adequately
after 10 years of program implementation; Podoconiosis is
deﬁned as being eliminated from a country when the following
four targets are achieved: 1) Prevalence of untreated podoconiosis
is maintained at less than 1%(among individuals >15 years old) in
100% of sample villages over a 10-year period. 2) Prevalence of
early signs of podoconiosis among children 10 to 15 years after
10 years of control program implementation is less than 1 in 10
000. 3) Greater than 95% of the population in endemic districts
wear protective shoes. 4) Greater than 95% of lymphoedema
cases are treated adequately. The assumption here is that if the
prevalence in an implementation unit is less than 1%, the formal
health sector can manage patients reactively, provided the
formal health sector is trained and equipped to do so, and preven-
tion activities can be run by the health system, without the need
for a control program.
Discussion
In 2011 WHO deﬁned podoconiosis as one of the NTDs, including
it under the ‘other conditions’ category.11 While this was a step
forward for the control of the disease, no clear targets or endem-
icity classiﬁcations exist. Such targets and deﬁnitions are import-
ant to consolidate efforts to control podoconiosis. Historically,
podoconiosis appears to have been eliminated from northern
Africa due to socioeconomic development and widespread shoe-
wearing practices,7 suggesting that podoconiosis elimination is
within our reach.
Using a Delphi assessment process, we deﬁned the endem-
icity threshold for podoconiosis to be ≥1%, the underlying
assumption being that in the absence of point-of-care diagnosis
Table 1. Characteristics of experts who completed the surveys
Characteristics First round
survey (n=28)
Second round
survey (n=25)
Age (years)
<35 12 (42.9%) 12 (48.0%)
35–45 10 (35.7%) 7 (28.0%)
45–54 2 (7.1%) 2 (8.0%)
55–64 3 (10.7%) 4 (16.0%)
≥65 1 (3.6%) 0
Gender
Female 8 (28.6%) 7 (28.0%)
Male 20 (71.4%) 18 (72.0%)
Education
MSc/MA/MPH 17 (60.7%) 13 (52.0%)
MD 4 (14.3%) 4 (16.0%)
PhD 7 (25.0%) 8 (32.0%)
Work unit
Global 8 (28.6%) 7 (28.0%)
National 20 (71.4%) 18 (72.0%)
Professional levela
Middle 8 (28.6%) 9 (36.0%)
Associate senior 12 (42.8%) 9 (36.0%)
Senior 8 (28.6%) 7 (28.0%)
Main area of expertise
Expert on podoconiosis 13 (46.4%) 13 (52.0%)
Expert on other NTDs 12 (42.9%) 9 (36.0%)
Expertise on podoconiosis
as well as other NTDs
3 (10.7%) 3 (12.0%)
a Middle: assistant researcher/lecturer/program manager;
Associate Senior: assistant/associate professor, national program
coordinator, clinician specialist; Senior: professor/director/senior
scientist.
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Table 2. Results of the ﬁrst round survey Delphi process for the development of case deﬁnitions, endemicity classiﬁcations and elimination targets
Survey items Mediana Modea CV Consensus (% score for
a survey item of >7)b
Section 1: case deﬁnitions
Suspected case: any lymphoedemac of the lower limb of any duration (at this stage we do not expect to make
a differential diagnosis but need to record the actual numbers of people with lymphoedema, even if a medical diagnosis
has not been conﬁrmed).
8.0 9.0 0.2 73.1
Probable case: any lymphoedemac of the lower limb present for more than 3 months in a resident of, or a long-term
visitor to, an endemic area.
7.5 8.0 0.3 57.7
Conﬁrmed case: lymphoedemac of the lower limb present for more than 3 months in a resident of, or long term visitor
to an endemic area, for which other causes have been excluded (onchocerciasis, LF, leprosy, Milroy syndrome, heart or
liver failure, etc).
8.0 9.0 0.1 88.5
Section 2: endemicity classiﬁcation
Non-endemic: <1% prevalence among adults ≥15 years old. 7.5 9.0 0.4 76.9
Hypo-endemic: ≥1 to <3% prevalence among adults ≥15 years old. 8.0 9.0 0.3 76.9
Meso-endemic: 3 to <10% prevalence among adults ≥15 years old. 8.0 9.0 0.3 76.9
Hyper-endemic: ≥10% prevalence among adults ≥15 years old. 8.0 9.0 0.3 76.9
Section 3: elimination
Elimination of podoconiosis from a district:
Prevalence is <1% (among individuals ≥15 years old) after 10 years of program implementation, AND 8.0 9.0 0.3 73.1
More than 90% of lymphoedema cases are treated adequately after 10 years of program implementation. 6.5 9.0 0.3 50.0
Elimination of podoconiosis from a country:
Prevalence of untreated podoconiosis is maintained at <1% (among individuals >15 years old) in 100% of sample
villages over a 10 year period, AND
7.0 9.0 0.3 61.5
Prevalence of early signs of podoconiosis among children aged 10–15 years after 10 years of control program
implementation is <1 in 10 000, AND
8.0 9.0 0.3 70.8
Greater than 95% of the population in endemic districts wear protective shoes, AND 8.5 9.0 0.2 76.9
Greater than 90% of lymphoedema cases are treated adequately. 7.0 9.0 0.3 61.5
Key indicators for the podoconiosis elimination monitoring:
Prevalence of podoconiosis (%): number of old and new cases of podoconiosis in the implementation unit (individuals
aged ≥15 years) divided by total population ≥15 years old in the same area, x 100.
9.0 9.0 0.2 84.6
Case detection rate (%): number of new cases of podoconiosis in the implementation unit divided by total population
at risk in the same area, x 100.
9.0 9.0 0.1 88.4
Treatment completion rate (%): number of patients that completed the required duration of treatment divided by all
new podoconiosis cases that started treatment in a given period, x 100.
8.5 9.0 0.2 86.9
Coverage of shoe wearing (%)(point prevalence in sampled villages): number of individuals wearing shoes (aged >1
year old) in implementation unit divided by total number of individuals aged >1 year old in the same area, x 100.
9.0 9.0 0.2 84.6
Section 4: monitoring clinical outcomes
Treatment completion: a patient who has completed the full course of the initial treatment given at health facility/
community level.
9.0 9.0 0.2 92.3
Defaulter: a patient who has been on treatment and whose treatment was interrupted for 2 or more consecutive
months.
8.0 9.0 0.3 73.1
Treatment success: treatment is successful if an incapacitated patient can assume normal activities following treatment. 8.0 9.0 0.3 69.2
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overestimation of cases may occur. In areas where there is no
podoconiosis or LF, the underlying prevalence of lymphoedema
is approximately 0.1–0.5%.27 Hence a threshold of ≥1% will
help take into account such residual lymphoedema cases. The
second rationale for such a cut-off point is that even if the 1%
of cases are conﬁrmed to be due to podoconiosis, the local
health system can respond without the need for establishing a
control program. Nonetheless, even in such cases, the health
providers working in the system should be given clear training
and be equipped with the necessary supplies.
We also generated endemicity classiﬁcations for podoconiosis.
Evidence from national and small-scale surveys indicates that
the prevalence of podoconiosis ranges from 1–10% with few
prevalence estimates >10% per district.17–19, 21 Three endemicity
classes will allow areas within the highest category to be priori-
tized and will enable monitoring of progress within these areas.
These thresholds are intended more to prioritize endemic imple-
mentation units (administrative units used as the basis for
making decisions aboutmorbiditymanagement), than to indicate
any particular biological consequences of disease prevalence in
contrast to infectious diseases.28
We have also produced targets for monitoring elimination of
podoconiosis. Since there is no biological cause of podoconiosis,
we cannot aim for interruption of transmission; the focus will be
on access to preventive and treatment services. The combination
of these elimination targets is intended to avoid the debates
such as those surrounding the leprosy elimination targets.29
Our targets address access to morbidity management for the
backlog of cases as well as prevention of new disease (monitored
through shoe-wearing practice and identiﬁcation of new cases
among children aged between 10–15 years). We suggest a 10
year time frame for the evaluation of control and elimination pro-
grams, given the challenge of addressing the backlog of cases and
addressing behavioral changewith regard to preventive behaviors
such as shoe wearing and regular foot hygiene practice. This will
also enable progress in reducing incident cases to be monitored.
Table 4 summarises the sources of data from which measures
of key indicators are likely to be derived. These include routine
sources (health management information systems and clinical
records) and speciﬁc patient and community surveys.
For the ﬁrst time, we have developed a case deﬁnition for podo-
coniosis which can be used within the routine surveillance system.
The sensitivity and speciﬁcity of our deﬁnition must be evaluated
in future studies. These broad deﬁnitions will capture individuals
with lymphoedema who may require foot care services. With
global movement towards integrated foot care services,30 identify-
ing the speciﬁc causes of lymphoedema may not be necessary.
While the deﬁnition here is sufﬁcient for surveillance purposes, if
identiﬁcation of the speciﬁc cause of lymphoedema is necessary,
conﬁrmatory tests to exclude other potential causes of lymphoe-
dema will be required until podoconiosis-speciﬁc point-of-care
diagnostic tools are developed. Other causes of lymphoedema
are excluded on the basis of history and physical examination.18,31
The diagnosis of podoconiosis is based on a history including details
of where in the lower limb the swelling started from, the age at
which swelling started and the presence of a family member
with similar conditions.31,32 Clinical examination for intact sensa-
tion in the lower leg, and the absence of swelling in the groin
area, is also important. In addition, podoconiosis patients must
be negative for all tests for LF.31
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Table 3. Results of the second round survey Delphi process for the development of case deﬁnitions, endemicity classiﬁcations and elimination targets
Survey items Mediana Modea CV Consensus (% score for
a survey item of >7)b
Section 1: case deﬁnitions
Suspected case: any lymphoedemac of the lower limb of any duration (at this stage we do not expect to make a
differential diagnosis but need to record the actual numbers of people with lymphoedema, even if a medical diagnosis
has not been conﬁrmed).
9.0 9.0 0.1 92.0
Probable case: any lymphoedemac of the lower limb present for more than 1 year in a resident of an endemic area. 8.0 9.0 0.3 76.0
Conﬁrmed case: lymphoedemac of the lower limb present for more than 1 year in a resident of an endemic area, for
which other causes have been excluded (onchocerciasis, LF, leprosy, Milroy syndrome, heart or liver failure, etc).
9.0 9.0 0.1 96.0
Section 2: endemicity classiﬁcation
Non-endemic: <1% prevalence among adults ≥15 years old. 9.0 9.0 0.3 76.0
Hypo-endemic: ≥1 to <3% prevalence among adults ≥15 years old. 8.0 8.0 0.2 84.0
Meso-endemic: 3 to <10% prevalence among adults ≥15 years old. 8.0 8.0 0.2 84.0
Hyper-endemic: ≥10% prevalence among adults ≥15 years old. 9.0 9.0 0.2 88.0
Section 3: elimination
Elimination of podoconiosis from a district:
The prevalence is <1% (among individuals ≥15 years old) after 10 years of program implementation, AND 8.0 9.0 0.2 92.0
More than 95% of lymphoedema cases are treated adequately after 10 years of program implementation. 9.0 9.0 0.1 88.0
Elimination of podoconiosis from a country:
Prevalence of untreated podoconiosis is maintained at <1% (among individuals >15 years old) in 100% of sample
villages over a 10 year period, AND
8.0 9.0 0.2 84.0
Prevalence of early signs of podoconiosis among children aged 10–15 years after 10 years of control program
implementation is <1 in 10 000, AND
9.0 9.0 0.2 88.0
Greater than 95% of the population in endemic districts wear protective shoes, AND 9.0 9.0 0.2 84.0
Greater than 95% of lymphoedema cases are treated adequately. 8.0 8.0 0.1 84.0
Key indicators for the podoconiosis elimination monitoring:
Prevalence of podoconiosis (%): number of old and new cases of podoconiosis in the implementation unit (individuals
aged ≥15 years) divided by the total population ≥15 years old in the same area, x 100.
9.0 9.0 0.1 96.0
Case detection rate (%): number of new cases of podoconiosis in the implementation unit divided by the total
population at risk in the same area, x 100.
9.0 9.0 0.1 100.0
Treatment completion rate (%): number of patients that completed the required duration of treatment divided by all
new podoconiosis cases that started treatment in a given period, x 100.
9.0 9.0 0.1 100.0
Coverage of shoe wearing (%)(point prevalence in sampled villages): number of individuals wearing shoes (aged >1
year old) in implementation unit divided by total number of individuals aged >1 year old in the same area, x 100.
9.0 9.0 0.1 92.0
Section 4: monitoring clinical outcomes
Treatment completion: a patient who has completed the full course of the initial treatment given at health facility/
community level.
9.0 9.0 0.1 96.0
Defaulter: a patient who has been on treatment and whose treatment was interrupted for 2 or more consecutive
months.
9.0 9.0 0.2 96.0
Treatment Success: treatment is successful if an incapacitated patient can assume normal activities following
treatment.
9.0 9.0 0.2 92.0
Continued
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Measuring clinical outcomes of indivduals with podoconiosis is a
complex phenomenon. Although simple lymphoedema manage-
ment for people with podoconiosis exists (i.e. foot hygiene, foot
and skin care, wound care, compression, exercises and elevation,
treatment of acute attack and use of shoes and socks to reduce
further exposure to the irritant soil),33–35 it has not been properly
evaluated or standardized. The duration of treatment and follow-
up frequency are areas currently under research. Therefore, only
three areas of clinical outcome (treatment completion, defaulter
and treatment success) are considered in the ‘monitoring clinical
outcomes’ deﬁnition (Table 3). Other areas of clinical outcome
will be deﬁned once the ongoing randomized controlled trial36 is
completed. Currently, a patient is regarded as having completed
treatment when he/she has followed supervised morbidity man-
agement for at least 3 months. Within these 3 months, if a
patient misses two consecutive monthly clinical appointments,
they are considered a defaulter. These end points are important
in monitoring the success of morbidity management programs.
The interventions for both prevention and treatment of podoco-
niosis are simple,9,34and short termgoals such as restored function
and improved quality of life can be achieved among lymphoedema
cases after just 3 months of treatment.33,34 Promotion of shoe
wearing for podoconiosis prevention may have multiple health
beneﬁts.37 Integrated morbidity management in the context
of foot care may become an important approach to avoid duplica-
tion of efforts and to utilize the available resources efﬁciently.
It is possible to integrate foot care services for podoconiosis with
those for Buruli ulcer, LF and leprosy.30 Currently the morbidity
management services are provided by very few faith-based organi-
zations and NGOs in endemic countries.33,34 Provision of free-of-
charge or low-cost prevention and treatment through government
programmes will be critical. People with podoconiosis are often
poor38 and marginalized due to their condition, and introduction
of user fees might hinder their access to the services.
Prevention of podoconiosis is an important component of
its elimination. Promotion of shoe wearing as a health interven-
tion should be advocated for.37 For those individuals who cannot
afford shoes themselves, subsidized shoe distribution should
be considered. Continued research should focus on identifying
point-of-care diagnostic tools for podoconiosis to ascertain cases
and verify elimination. At the start of elimination programs, deﬁni-
tive diagnosis may not be a priority, but as the ‘end game’
approaches, robust, sensitive and speciﬁc diagnostic tests will be
required. In the earlier phases of elimination, a syndromic approach
may sufﬁce for the diagnosis of podoconiosis.31 In the long term,
identiﬁcation of biomarkers of podoconiosis will be vital.
With all these important ﬁndings our study is not without lim-
itations. First, research into and intervention against podoconiosis
are currently present in only a few endemic countries, so there
are few experts in podoconiosis. Nonetheless, we have included
almost all the top experts in podoconiosis research and program-
ing working in endemic counties globally. Second, there are many
important questions unanswered so far about podoconiosis, such
as treatment duration and outcomes. This means that there is a
need to deﬁne these indicators once appropriate evidence is gen-
erated. Third, full operationalisation of several components of the
case deﬁnitions and elimination targets is still in progress. Oper-
ational deﬁnition of ‘adequate treatment’ of lymphoedema is
an issue being explored in relation to lymphatic ﬁlariasis as well
as podoconiosis. Similarly ‘practicing proper foot hygiene’ and
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Table 4. Sources of data
Indicators Measure Data source
Section 1: case deﬁnition
Suspected cases Number of suspected cases of podoconiosis Clinical record or HMIS
Probable cases Number of probable cases of podoconiosis Clinical record or HMIS
Conﬁrmed cases Number of conﬁrmed cases of podoconiosis Clinical record or HMIS
Section 2: endemicity classiﬁcation
Non-endemic IUs Number of non-endemic IUs Mapping and evaluation surveys
Hypo-endemic IUs Number of hypo-endemic IUs Mapping and evaluation surveys
Meso-endemic IUs Number of meso-endemic IUs Mapping and evaluation surveys
Hyper-endemic IUs Number of hyper-endemic IUs Mapping and evaluation surveys
Section 3: elimination
Elimination of podoconiosis from an IU:
Prevalence of untreated podoconiosis (among individuals aged ≥15
years) in an endemic IU
Prevalence of podoconiosis Mapping and evaluation surveys
Percent of lymphoedema cases treated adequately Percentage cases of lymphoedema treated adequately Evaluation surveys
Prevalence of early signs of podoconiosis among children aged 10–15
years in an endemic IU
Prevalence of early signs of podoconiosis Mapping and evaluation surveys
Proportion of the population in an endemic IU wearing protective shoes Proportion of individuals wearing shoes Mapping and evaluation surveys
Key indicators for the podoconiosis elimination monitoring:
Case detection rate: proportion of patients newly diagnosed
withpodoconiosis in the IU
Proportion of new cases of podoconiosis in the IU Community-based survey and
clinical record or HMIS
Treatment completion rate: proportion of patients that completed the
required duration of treatment divided by all patients newly diagnosed
with podoconiosis that started treatment in a given period
Proportion of patients that completed the required
duration of treatment
Podoconiosis patient survey or
clinical record or HMIS
Section 4: monitoring clinical outcomes
Defaulter rate: percentage of patients with default treatment Percentage of patients who experienced default
treatment
Podoconiosis patient survey and
clinical record review or HMIS
Treatment success 1: deﬁned as the proportion of advanced stage patients
(podoconiosis clinical stage 3, 4 or 5)45 who can resume normal activities
following treatment, maintained over a follow-up period of 1 year.
Proportion of advanced stage podoconiosis patients
who resumed normal activities, maintained for a
1 year period
Podoconiosis patient survey and
clinical record review or HMIS
Treatment success 2: deﬁned as the proportion of early stage patients
(clinical stage 1 or 2)45 with one stage decrease after completion of
treatment, maintained for over a period of 1 year.
Proportion of early stage podoconiosis patients who
decreased one stage after completion of treatment,
maintained for 1 year
Podoconiosis patient survey and
clinical record review or HMIS
Key indicators for monitoring progress:
Proportion of the population in the endemic districts that practice proper
foot hygiene (measured for the last 1 year)
Proportion of individuals who practice proper
foot hygiene
Community-based survey
HMIS: health management information system; IU: implementation unit (administrative units used as the basis for making decisions about morbidity management).
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‘wearing protective footwear’ will both require robust operational
deﬁnitions.
Conclusions
Untreated lymphoedema due to podoconiosis causes signiﬁcant
deformity, disability, social and productivity loss in endemic coun-
tries.38–40 The disabilities associated with podoconiosis are pre-
ventable with simple preventive measures (consistent shoe
wearing and foot hygiene) and early lymphoedema morbidity
management.18,34 These simple interventions can be integrated
into the health system and delivered at low cost.41 It is time to
capitalize on the experience of some endemic countries and
provide the intervention sustainably and at scale, with clear
aims and targets.33,35,42,43 Deﬁning elimination targets and
endemicity classiﬁcation is critical for mobilizing communities
and stakeholders and ensuring accountability in relation to elim-
ination of podoconiosis. The indicators described here may serve
as a starting point towards a global strategy for podoconiosis
elimination.
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